生脉散治疗心肌梗死的系统评价

Shengmai powders for patients with myocardial infarction: a systematic review

[目的]系统评价西药常规加生脉散与单纯西药常规治疗心肌梗死的临床疗效。[方法]计算机检索中国知网(CNKI)、中国生物医学文献数据库(CBM)、维普(VIP)、万方、Pub Med、EMbase、Cochrane图书馆和Web of Science,搜集西药常规加生脉散与单纯西药常规治疗心肌梗死的临床随机对照试验。按照Cochrane协作网等推荐的方法评价纳入研究的方法学质量和提取有效数据后,采用Rev Man5.3.0软件进行Meta分析。[结果]共纳入11个研究,合计766例患者,其研究质量均为C级。Meta分析结果显示:西药常规加生脉散与单纯西药常规治疗比较,能显著提高心肌梗死临床综合疗效[OR=2.82,95%CI(1.57,5.50),P=0.000 5];减少心肌梗死后心血管事件的发生[OR=0.29,95%CI(0.15,0.54),P=0.000 1];降低内皮素水平[MD=-16.69,95%CI(-24.79,-8.60),P<0.000 1]。[结论]西药常规加生脉散较单纯西药常规治疗,可提高心肌梗死患者的临床疗效。

[Objective] To evaluate the clinical therapeutic effect of western medicine plus Shengmai powers versus simple western medicine in myocardial infarction（MI） patients. [Methods] We systematically searched the CNKI,CBM, VIP, Wanfang, Pub Med, Cochrane Library, Web of science and other related periodicals to identify randomized controlled trials（RCTs）. The quality of studies was evaluated according to methods of the Cochrane Collaboration, the data were extracted; and meta-analyses were performed with Rev Man5.3.0 soft ware. [Results]Eleven trials involving 766 patients were included. The results of meta-analyses showed that compared with the simple western medicine treatment, the combination of western medicine and Shengmai powers therapy significantly improved the symptoms, clinical comprehensive effect [OR =2.82,95% CI（1.57,5.50）,P =0.000 5], reduce the incidence of cardiovascular events after myocardial infarction[OR=0.29,95%CI（0.15,0.54）,P=0.000 1], reduce the plasma endothelin level [MD=-16.69,95%CI（-24.79,-8.60）,P0.000 1]. [Conclusion] The therapeutic effect of combining western medicine with Shengmai powers therapy on myocardial infarction patients is better than that of simple western medicine treatment.